Derik De Bruin
Stock Analyst at B of A Securities
(4.95)
# 12
Out of 4,778 analysts
210
Total ratings
64.34%
Success rate
83.86%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $9.74 | +12.94% | 13 | Mar 3, 2025 | |
| EXAS Exact Sciences | Maintains: Buy | $72 → $65 | $45.67 | +42.33% | 7 | Feb 20, 2025 | |
| NEO NeoGenomics | Maintains: Neutral | $19 → $16 | $9.96 | +60.64% | 5 | Feb 19, 2025 | |
| WAT Waters | Maintains: Neutral | $430 → $410 | $368.63 | +11.22% | 13 | Feb 13, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $156 | $120.50 | +29.46% | 32 | Jan 27, 2025 | |
| RVTY Revvity | Upgrades: Buy | $138 | $107.41 | +28.48% | 2 | Dec 13, 2024 | |
| TMO Thermo Fisher Scientific | Maintains: Buy | $675 → $660 | $514.16 | +28.36% | 18 | Dec 13, 2024 | |
| IQV IQVIA Holdings | Maintains: Buy | $255 → $235 | $181.36 | +29.58% | 3 | Dec 13, 2024 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $220 → $210 | $161.38 | +30.13% | 5 | Dec 13, 2024 | |
| WST West Pharmaceutical Services | Maintains: Buy | $350 → $355 | $225.88 | +57.17% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $21.13 | +23.05% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $234.45 | +15.59% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $165.73 | +9.82% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $78 → $80 | $43.21 | +85.14% | 12 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $290 | $212.48 | +36.48% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $13 → $15 | $21.50 | -30.23% | 4 | Aug 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $8.74 | +140.41% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $25 | $9.71 | +157.60% | 8 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $21.45 | +49.18% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $87.50 | +14.29% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $60.78 | +41.49% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.53 | +268.27% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1,650 → $1,525 | $1,195.74 | +27.54% | 9 | May 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.81 | +260.11% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $179.01 | +45.24% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $7.11 | +1,587.76% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $63 | $39.67 | +57.78% | 5 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $161.37 | -25.64% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $2.75 | +227.27% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $418.11 | -43.79% | 3 | Nov 2, 2018 |
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $9.74
Upside: +12.94%
Exact Sciences
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $45.67
Upside: +42.33%
NeoGenomics
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $9.96
Upside: +60.64%
Waters
Feb 13, 2025
Maintains: Neutral
Price Target: $430 → $410
Current: $368.63
Upside: +11.22%
Agilent Technologies
Jan 27, 2025
Maintains: Neutral
Price Target: $150 → $156
Current: $120.50
Upside: +29.46%
Revvity
Dec 13, 2024
Upgrades: Buy
Price Target: $138
Current: $107.41
Upside: +28.48%
Thermo Fisher Scientific
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $514.16
Upside: +28.36%
IQVIA Holdings
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $181.36
Upside: +29.58%
Charles River Laboratories International
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $161.38
Upside: +30.13%
West Pharmaceutical Services
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $225.88
Upside: +57.17%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $21.13
Upside: +23.05%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $234.45
Upside: +15.59%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $165.73
Upside: +9.82%
Dec 13, 2024
Maintains: Buy
Price Target: $78 → $80
Current: $43.21
Upside: +85.14%
Dec 13, 2024
Upgrades: Buy
Price Target: $290
Current: $212.48
Upside: +36.48%
Aug 30, 2024
Maintains: Underperform
Price Target: $13 → $15
Current: $21.50
Upside: -30.23%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $8.74
Upside: +140.41%
Jul 18, 2024
Maintains: Neutral
Price Target: $36 → $25
Current: $9.71
Upside: +157.60%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $21.45
Upside: +49.18%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $87.50
Upside: +14.29%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $60.78
Upside: +41.49%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.53
Upside: +268.27%
May 8, 2023
Maintains: Neutral
Price Target: $1,650 → $1,525
Current: $1,195.74
Upside: +27.54%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.81
Upside: +260.11%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $179.01
Upside: +45.24%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $7.11
Upside: +1,587.76%
Oct 6, 2020
Upgrades: Buy
Price Target: $63
Current: $39.67
Upside: +57.78%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $161.37
Upside: -25.64%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $2.75
Upside: +227.27%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $418.11
Upside: -43.79%